Important announcement regarding the weight loss drug Mounjaro/Tirzepatide
On Friday afternoon the ICB have advised how we are to start this service here at the practice. Mounjaro/tirzepatide will be come eligible to people in cohorts. The first cohort will be for those with a BMI of 40 or greater and 4 or more of the following conditions: high blood pressure, high cholesterol, heart disease, diabetes type 2, and obstructive sleep apnoea. We will contact all eligible patients: you do not need to contact us to enquire. If you haven’t updated your weight/BMI with us in a while please use our Patient POD. We will be using this as a source of information to help determine eligible patients. Please DO NOT book appointments with clinicians to discuss starting this. We will contact you.